TG Therapeutics Announces Data Presentations for BRIUMVI® at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting
Rhea-AI Summary
TG Therapeutics (NASDAQ:TGTX) outlined four data presentations on BRIUMVI (ublituximab-xiiy) in adults with relapsing multiple sclerosis at the 2026 CMSC meeting in Charlotte, May 27-29, 2026.
Presentations feature Phase 4 ENABLE patient‑reported outcomes, real‑world transition data, infusion tolerability, and the PROVIDE breast milk study.
AI-generated analysis. Not financial advice.
Positive
- None.
Negative
- None.
News Market Reaction – TGTX
On the day this news was published, TGTX gained 2.21%, reflecting a moderate positive market reaction. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $132M to the company's valuation, bringing the market cap to $6.08B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers show mixed moves: MRUS -7.08%, PTCT -1.12%, CRSP +0.83%, RNA +0.61%, LEGN +6.8%. With TGTX down 0.94% and no peers in the momentum scanner, trading appears company-specific rather than a coordinated biotech rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| May 06 | Earnings, guidance raise | Positive | +16.3% | Strong Q1 2026 revenue and higher BRIUMVI guidance drove a sharp gain. |
| May 05 | Earnings update | Positive | +1.1% | Precision BioSciences reported Q1 results and pipeline progress with modest uptick. |
| Apr 30 | Earnings call notice | Neutral | +0.6% | Announcement of upcoming Q1 2026 call and business update prompted slight rise. |
| Apr 22 | Conference data presentations | Positive | +4.8% | BRIUMVI data presentations at AAN 2026 supported shares with a solid gain. |
| Apr 15 | Clinical enrollment complete | Positive | +0.1% | Completion of enrollment for Phase 3 subcutaneous BRIUMVI led to a small rise. |
Recent TG Therapeutics news, especially BRIUMVI-focused and earnings events, has typically seen positive price reactions, suggesting the stock has responded well to fundamental and clinical updates.
Over the past months, TG Therapeutics highlighted strong BRIUMVI momentum, with Q1 2026 results and raised revenue guidance on May 6 followed by a 16.26% gain. Earlier in April, the company announced data presentations at the American Academy of Neurology 2026 and completion of enrollment for a Phase 3 subcutaneous BRIUMVI trial, both met with small positive moves. Conference-call scheduling also drew a mild uptick, underscoring constructive reactions to execution milestones.
Regulatory & Risk Context
The company has an effective S-3ASR shelf registration filed on 2025-08-08, allowing issuance of various securities over time; reported usage_count is 0, indicating no takedowns disclosed under this shelf to date.
Market Pulse Summary
This announcement highlights additional BRIUMVI data across Phase 4 ENABLE and Phase 3 ULTIMATE programs, emphasizing strong disease control, low relapse rates, and favorable infusion characteristics. It adds to a sequence of recent BRIUMVI-focused communications, including earlier conference presentations and ongoing subcutaneous development. Investors may watch for how these patient-reported outcomes and real-world metrics integrate with future earnings, guidance updates, and forthcoming late-stage readouts discussed in prior disclosures.
Key Terms
phase 4 medical
phase 3 medical
annualized relapse rate medical
anti-cd20 therapies medical
observational study medical
oral presentation technical
AI-generated analysis. Not financial advice.
NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in adults with relapsing forms of multiple sclerosis (RMS) at the 2026 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting, being held May 27-29, 2026 in Charlotte, N.C. Abstracts are available on the CMSC website at http://www.mscare.org/2026 and data presentations are also available and can be accessed either on the 2026 CMSC meeting app or on TG’s website at www.tgtherapeutics.com/publications. All TG data will be presented by the respective authors during the CMSC conference on Thursday, May 28th, 2026. Additional details of the presentation schedule can be found below.
Michael S. Weiss, Chief Executive Officer and Chairman of TG Therapeutics stated, “We are pleased to present four data presentations at CMSC 2026 that continue to reinforce the differentiated clinical profile of BRIUMVI in relapsing multiple sclerosis. Importantly, new analyses from our ongoing ENABLE Phase 4 study will be featured in an oral presentation and demonstrate significant and durable improvements in patient-reported outcomes, including treatment satisfaction and physical and psychological impact measures, with benefits observed as early as Day 15 and sustained through Week 48. In addition, real-world data evaluating patients transitioning from prior anti-CD20 therapies to BRIUMVI showed strong disease control, with
The real-world analyses complement earlier findings from our ULTIMATE Phase 3 clinical program, demonstrating low rates of infusion-related reactions which were predominantly mild events, and a consistent one-hour infusion administration following the initial dose. Collectively, these data further support BRIUMVI’s ability to deliver a differentiated treatment experience for people living with RMS in both clinical trial and real-world settings.”
TG PRESENTATION SCHEDULE:
Oral Presentation Title: Ublituximab Significantly Improves Patient-Reported Outcomes: Results from the Phase 4 Observational Study ENABLE
- Presentation Date/Time: Thurs. May 28, 3:40pm – 4:00pm ET
- Session: Charlotte Convention Center E216ABCD
- Abstract & Poster Number: #10980/DMT03
- Presenting Author: Dr. Carrie Hersh - Lou Ruvo Center for Brain Health, Cleveland Clinic, Las Vegas, NV
Poster Presentation Title: Real-World Transition to Ublituximab from Prior Anti-CD20 Treatment in the Phase 4 ENABLE Study
- Presentation Date/Time: Thurs. May 28, 5:00pm – 7:00pm ET
- Session: Exhibit Hall B
- Abstract & Poster Number: #11084/DMT12
- Presenting Author: Dr. Angel Chinea - Centro Internacional De Mercadeo, Guaynabo, PR
Poster Presentation Title: Evaluation of Ublituximab Infusion Tolerability: Analysis of Data Following the ULTIMATE Phase 3 Studies
- Presentation Date/Time: Thurs. May 28, 5:00pm – 7:00pm ET
- Session: Exhibit Hall B
- Abstract & Poster Number: #11078/DMT45
- Presenting Author: Rachel Duke, MSM, PA-C, MSCS - University of South Florida, Tampa, FL
Poster Presentation Title: Evaluating the Presence and Concentration of Briumvi in Breast Milk (PROVIDE): An Interim Report
- Presentation Date/Time: Thurs. May 28, 5:00pm – 7:00pm ET
- Session: Exhibit Hall B
- Abstract & Poster Number: #11032/DMT47
- Presenting Author: Dr. Riley Bove - UCSF Weill Institute of Neurosciences, Department of Neurology, University of California San Francisco, San Franciso, CA
The data presentations are now available on the Publications page, located within the Pipeline section, of the Company’s website at www.tgtherapeutics.com/publications.cfm.
ABOUT THE ULTIMATE I & II PHASE 3 TRIALS
ULTIMATE I & II are two randomized, double-blind, double-dummy, parallel group, active comparator-controlled clinical trials of identical design, in patients with RMS treated for 96 weeks. Patients were randomized to receive either BRIUMVI, given as an IV infusion of 150 mg administered in four hours, 450 mg two weeks after the first infusion administered in one hour, and 450 mg every 24 weeks administered in one hour, with oral placebo administered daily; or teriflunomide, the active comparator, given orally as a 14 mg daily dose with IV placebo administered on the same schedule as BRIUMVI. Both studies enrolled patients who had experienced at least one relapse in the previous year, two relapses in the previous two years, or had the presence of a T1 gadolinium (Gd)-enhancing lesion in the previous year. Patients were also required to have an Expanded Disability Status Scale (EDSS) score from 0 to 5.5 at baseline. The ULTIMATE I & II trials enrolled a total of 1,094 patients with RMS across 10 countries. These trials were led by Lawrence Steinman, MD, Zimmermann Professor of Neurology & Neurological Sciences, and Pediatrics at Stanford University. Additional information on these clinical trials can be found at www.clinicaltrials.gov (NCT03277261; NCT03277248).
ABOUT BRIUMVI® (ublituximab-xiiy) 150 mg/6 mL Injection for IV
BRIUMVI is a novel monoclonal antibody that targets a unique epitope on CD20-expressing B-cells. Targeting CD20 using monoclonal antibodies has proven to be an important therapeutic approach for the management of autoimmune disorders, such as RMS. BRIUMVI is uniquely designed to lack certain sugar molecules normally expressed on the antibody. Removal of these sugar molecules, a process called glycoengineering, allows for efficient B-cell depletion at low doses.
BRIUMVI is indicated in the U.S. for the treatment of adults with RMS, including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease and in several countries outside of the U.S. for the treatment of adult patients with RMS with active disease defined by clinical or imaging features.
A list of authorized specialty distributors can be found at www.briumvi.com.
IMPORTANT SAFETY INFORMATION
Contraindications: BRIUMVI is contraindicated in patients with:
Active Hepatitis B Virus infection
A history of life-threatening infusion reaction to BRIUMVI
WARNINGS AND PRECAUTIONS
Infusion Reactions: BRIUMVI can cause infusion reactions, which can include pyrexia, chills, headache, influenza-like illness, tachycardia, nausea, throat irritation, erythema, and an anaphylactic reaction. In MS clinical trials, the incidence of infusion reactions in BRIUMVI-treated patients who received infusion reaction-limiting premedication prior to each infusion was
Observe treated patients for infusion reactions during the infusion and for at least one hour after the completion of the first two infusions unless infusion reaction and/or hypersensitivity has been observed in association with the current or any prior infusion. Inform patients that infusion reactions can occur up to 24 hours after the infusion. Administer the recommended pre-medication to reduce the frequency and severity of infusion reactions. If life-threatening, stop the infusion immediately, permanently discontinue BRIUMVI, and administer appropriate supportive treatment. Less severe infusion reactions may involve temporarily stopping the infusion, reducing the infusion rate, and/or administering symptomatic treatment.
Infections: Serious, life-threatening or fatal, bacterial and viral infections have been reported in BRIUMVI-treated patients. In MS clinical trials, the overall rate of infections in BRIUMVI-treated patients was
Consider the potential for increased immunosuppressive effects when initiating BRIUMVI after immunosuppressive therapy or initiating an immunosuppressive therapy after BRIUMVI.
Hepatitis B Virus (HBV) Reactivation: HBV reactivation occurred in an MS patient treated with BRIUMVI in clinical trials. Fulminant hepatitis, hepatic failure, and death caused by HBV reactivation have occurred in patients treated with anti-CD20 antibodies. Perform HBV screening in all patients before initiation of treatment with BRIUMVI. Do not start treatment with BRIUMVI in patients with active HBV confirmed by positive results for HB surface antigen (HBsAg) and anti-HB tests. For patients who are negative for HBsAg and positive for HB core antibody [HBcAb+] or are carriers of HBV [HBsAg+], consult a liver disease expert before starting and during treatment.
Progressive Multifocal Leukoencephalopathy (PML): PML is an opportunistic viral infection of the brain caused by the JC virus (JCV) that typically only occurs in patients who are immunocompromised, and that usually leads to death or severe disability. JCV infection resulting in PML has been observed in patients treated with anti-CD20 antibodies, including BRIUMVI, and other MS therapies.
If PML is suspected, withhold BRIUMVI and perform an appropriate diagnostic evaluation. Typical symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body or clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes.
MRI findings may be apparent before clinical signs or symptoms; monitoring for signs consistent with PML may be useful. Further investigate suspicious findings to allow for an early diagnosis of PML, if present. Following discontinuation of another MS medication associated with PML, lower PML-related mortality and morbidity have been reported in patients who were initially asymptomatic at diagnosis compared to patients who had characteristic clinical signs and symptoms at diagnosis.
If PML is confirmed, treatment with BRIUMVI should be discontinued.
Vaccinations: Administer all immunizations according to immunization guidelines: for live or live-attenuated vaccines, at least 4 weeks and, whenever possible, at least 2 weeks prior to initiation of BRIUMVI for non-live vaccines. BRIUMVI may interfere with the effectiveness of non-live vaccines. The safety of immunization with live or live-attenuated vaccines during or following administration of BRIUMVI has not been studied. Vaccination with live virus vaccines is not recommended during treatment and until B-cell repletion.
Vaccination of Infants Born to Mothers Treated with BRIUMVI During Pregnancy: In infants of mothers exposed to BRIUMVI during pregnancy, assess B-cell counts prior to administration of live or live-attenuated vaccines as measured by CD19+ B-cells. Depletion of B-cells in these infants may increase the risks from live or live-attenuated vaccines. Inactivated or non-live vaccines may be administered prior to B-cell recovery. Assessment of vaccine immune responses, including consultation with a qualified specialist, should be considered to determine whether a protective immune response was mounted.
Fetal Risk: Based on data from animal studies, BRIUMVI may cause fetal harm when administered to a pregnant woman. Transient peripheral B-cell depletion and lymphocytopenia have been reported in infants born to mothers exposed to other anti-CD20 B-cell depleting antibodies during pregnancy. Advise females of reproductive potential to use effective contraception during BRIUMVI treatment and for 6 months after the last dose.
Reduction in Immunoglobulins: As expected with any B-cell depleting therapy, decreased immunoglobulin levels were observed. Decrease in immunoglobulin M (IgM) was reported in
Liver Injury: Clinically significant liver injury, without findings of viral hepatitis, has been reported in the postmarketing setting in patients treated with anti-CD20 B-cell depleting therapies approved for the treatment of MS, including BRIUMVI. Signs of liver injury, including markedly elevated serum hepatic enzymes with elevated total bilirubin, have occurred from weeks to months after administration.
Patients treated with BRIUMVI found to have an alanine aminotransaminase (ALT) or aspartate aminotransferase (AST) greater than 3x the upper limit of normal (ULN) with serum total bilirubin greater than 2x ULN are potentially at risk for severe drug-induced liver injury.
Obtain liver function tests prior to initiating treatment with BRIUMVI, and monitor for signs and symptoms of any hepatic injury during treatment. Measure serum aminotransferases, alkaline phosphatase, and bilirubin levels promptly in patients who report symptoms that may indicate liver injury, including new or worsening fatigue, anorexia, nausea, vomiting, right upper abdominal discomfort, dark urine, or jaundice. If liver injury is present and an alternative etiology is not identified, discontinue BRIUMVI.
Most Common Adverse Reactions: The most common adverse reactions in RMS trials (incidence of at least
Physicians, pharmacists, or other healthcare professionals with questions about BRIUMVI should visit www.briumvi.com.
ABOUT BRIUMVI PATIENT SUPPORT in the U.S.
BRIUMVI Patient Support is a flexible program designed by TG Therapeutics to support U.S. patients through their treatment journey in a way that works best for them. More information about the BRIUMVI Patient Support program can be accessed at www.briumvipatientsupport.com.
ABOUT MULTIPLE SCLEROSIS
Relapsing multiple sclerosis (RMS) is a chronic demyelinating disease of the central nervous system (CNS) and includes people with relapsing-remitting multiple sclerosis (RRMS) and people with secondary progressive multiple sclerosis (SPMS) who continue to experience relapses. RRMS is the most common form of multiple sclerosis (MS) and is characterized by episodes of new or worsening signs or symptoms (relapses) followed by periods of recovery. It is estimated that nearly 1 million people are living with MS in the United States and approximately
ABOUT TG THERAPEUTICS
TG Therapeutics is a fully integrated, commercial stage, biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI® (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features. For more information, visit www.tgtherapeutics.com, and follow us on X (formerly Twitter) @TGTherapeutics and on LinkedIn.
BRIUMVI® is a registered trademark of TG Therapeutics, Inc.
Cautionary Statement
This press release contains forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward- looking statements contained in this press release. In addition to the risk factors identified from time to time in our reports filed with the U.S. Securities and Exchange Commission (SEC), factors that could cause our actual results to differ materially include the below.
Such forward looking statements include but are not limited to statements regarding the ULTIMATE I & II Phase 3 studies, the ENABLE study, the PROVIDE study and BRIUMVI as a treatment for relapsing forms of multiple sclerosis (RMS). Additional factors that could cause our actual results to differ materially include the following: the risk that the data from any studies evaluating BRIUMVI that we announce or publish may change, or the product profile of BRIUMVI may be impacted, as more data or additional endpoints are analyzed; the risk that data may emerge from future clinical studies or from adverse event reporting that may affect the safety and tolerability profile and commercial potential of BRIUMVI; the risk that any individual patient’s clinical experience in the post-marketing setting, or the aggregate patient experience in the post-marketing setting, may differ from that demonstrated in controlled clinical trials such as ULTIMATE I and II; our ability to expand our commercial infrastructure, and successfully market and sell BRIUMVI in RMS; the Company’s reliance on third parties for manufacturing, distribution and supply, and a range of other support functions for our commercial and clinical products, including BRIUMVI, and the ability of the Company and its manufacturers and suppliers to produce and deliver BRIUMVI to meet the market demand for BRIUMVI; the failure to obtain and maintain requisite regulatory approvals, including the risk that the Company fails to satisfy post-approval regulatory requirements; the uncertainties inherent in research and development and general political, economic and business conditions. Further discussion about these and other risks and uncertainties can be found in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and in our other filings with the U.S. Securities and Exchange Commission.
Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at www.tgtherapeutics.com. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only.
CONTACT:
Investor Relations
Email: ir@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 4
Media Relations:
Email: media@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 6
1. MS Prevalence. National Multiple Sclerosis Society website. https://www.nationalmssociety.org/About-the-Society/MS-Prevalence. Accessed October 26, 2020. 2. Multiple Sclerosis Internation
